Peter Schmidt - PARKINSONS

The greatest issue facing Parkinson’s patients today is the lack of any therapy that could slow the disease progression.  In its early and mid stages, Parkinson’s primarily affects the dopamine system and, as we have seen in studies of placebo response, the dopamine system responds to hope.  The impact of a therapy that can slow the disease would go beyond just the benefit of neuroprotection, it would help people with Parkinson’s to see a brighter future.  Research has shown that the placebo response in randomized trials is affected by the probability of the s

Peter Schmidt

Todd Sherer - PARKINSONS

Parkinson’s patients need a cure. The millions living with the disease today, the many more who will age into Parkinson’s risk and their loved ones need a therapy that could prevent, stop or halt progression of the disease. No current treatments impact the disease process itself; they only treat the symptoms. In addition, the symptomatic treatments at our disposable leave much to be desired. Some symptoms — such as cognitive decline — have no therapeutic option.

Todd Sherer


Because Parkinson’s is a chronic illness, the issues that face persons with Parkinson’s disease vary with the stage of the disease.   One challenge for research is how best to improve quality of life across the span of this disease.  This past fall and winter the NINDS and the Parkinson’s community wrestled with this challenge in developing research recommendations for Parkinson’s disease (PD recommendations for research



Like most Parkinson’s organisations, the European Parkinson’s Disease Association (EPDA) believes there are many hurdles to overcome if people with Parkinson’s (PwPs) lives are to improve across Europe and the globe.

But, perhaps unusually, the EPDA’s priorities are not focused on research for new treatments or even a cure. Instead, the main challenges from our organisation’s point of view revolve around the fact that the majority of PwPs are not currently able to lead a dignified life that they are in control of.


Gabriela Lavezzari - PARKINSONS

Parkinson’s disease, a chronic, progressive neurological condition that affects 1.5 million in the United States and costs the American economy more than $14 billion annually, is one of the most mysterious challenges facing the biopharmaceutical industry today. The symptoms of the disease – tremors, difficulty speaking and swallowing and instability – are well-known and evident. But to develop treatments to help those already with the disease and the 60,000 additional individuals who develop the condition every year, remains a challenge.

Gabriela Lavezzari


Subscribe to PhRMA RSS